Medtronic Diabetes today announced the expansion of U.S. pharmacy formulary access for its MiniMed™ 780G insulin pump, through agreements with major pharmacy benefit managers (PBMs) and PBM group purchasing organizations (GPOs), including Ascent and Zinc. These agreements also include access to Medtronic Diabetes’ expanded CGM portfolio — Simplera™ sensor, Simplera Sync™ sensor, and Instinct™ sensor, made by Abbott — and build on existing pharmacy coverage for Medtronic CGMs and consumables, such as infusion sets and reservoirs.

Our dedicated payer account team is actively collaborating with downstream health plans partnered with these PBMs to further expand coverage of the MiniMed™ 780G system under the pharmacy benefit. These access gains strengthen our end-to-end access to Medtronic Diabetes technologies through the pharmacy channel.

“Expanding pharmacy benefit coverage for the MiniMed™ 780G system is an important step forward in how people access automated insulin delivery,” said Que Dallara, EVP & President of Medtronic Diabetes. “Access through the pharmacy channel can help lower upfront costs compared to traditional durable medical equipment (DME) pathways and make it easier for people to get started on therapy. It also allows patients and care teams to better align pumps, sensors, and consumables under a single coverage pathway, supporting greater predictability when navigating access.”

To support a streamlined experience, providers can prescribe the MiniMed™ 780G system, and Medtronic Diabetes will continue to manage benefit investigation across both pharmacy and DME options. This established approach provides transparency into available coverage pathways and helps customers choose the options that best meets their needs.

To help advance access to diabetes technology, Medtronic Diabetes offers programs, including financial assistance, flexible payment and co-pay programs, trial programs and more designed to support eligible customers.

About the Diabetes Business at Medtronic
Medtronic Diabetes is on a mission to make diabetes more predictable, so everyone can embrace life to the fullest with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Janet Cho
Communications
+1 (818) 403-7028

Ryan Weispfenning
Investor Relations
+1 (763) 505-4626